Ultragenyx Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Ultragenyx Value Chain Analysis helps you understand how the company creates value through its support and primary activities in a clear, structured format. The page already shows a real preview of the actual deliverable, so you can review the content before buying. Purchase the full version to access the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
Ultragenyx's firm infrastructure centers on rare-disease governance, regulatory compliance, and capital allocation across its commercial products and pipeline. The company's 2025 Form 10-K shows it remains a development-heavy business, so finance, legal, quality, and medical teams must stay tightly aligned to support FDA and global filing work. That structure helps it manage small patient pools, high compliance risk, and long R&D cycles.
Human Resource Management
Ultragenyx's human resource management depends on rare-disease talent in clinical development, gene therapy, biologics, regulatory affairs, and specialty commercialization. Hiring and keeping these experts helps it move programs faster from trials to launch and strengthen patient support, which matters in a business where execution speed can change approval and uptake odds.
Technology Development
In fiscal 2025, Ultragenyx kept its technology focus on enzyme replacement, gene therapy, and small molecules for ultra-rare genetic diseases. Its R&D engine adds value by moving programs from discovery to clinical proof with biomarkers, translational science, and small trials, which is vital when patient pools can be under 100 in a study.
This model helps lower clinical risk before larger spend kicks in, so each step in proof of mechanism matters.
Procurement
Ultragenyx's procurement centers on specialized suppliers, contract manufacturing, and clinical trial services that can meet biologics and gene-therapy quality rules. For small-volume, high-value drugs, tight supplier controls help reduce batch failure, cold-chain, and launch-delay risk. In 2025, this matters most for ULTOMIRIS-like rare-disease assets, where one delayed component can interrupt patient supply and raise costs fast.
Ultragenyx's 2025 rare-disease engine stays tightly aligned
In 2025, Ultragenyx's support activities stayed built for rare-disease execution: tight governance, specialized hiring, translational R&D, and strict supplier control. Its 2025 Form 10-K still shows a development-heavy model, so finance, legal, quality, and medical teams must stay aligned. Small trials can involve under 100 patients, so each process step matters.
| Support activity | 2025 signal |
|---|---|
| Infrastructure | 2025 Form 10-K |
| HR | Rare-disease talent |
| Technology | Small trials under 100 |
| Procurement | Specialized suppliers |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Ultragenyx's inbound logistics centers on controlled receipt of active ingredients, clinical trial supplies, biologic inputs, and packaging parts, with 2°C to 8°C cold-chain control for temperature-sensitive products. Rare-disease therapies are low-volume but high-value, so supplier qualification and lot traceability matter more than scale. In 2025, this setup supports its 9 approved medicines and helps protect product quality, trial continuity, and launch timing.
Operations
Ultragenyx's Operations turn science into approved medicines through R&D, clinical trials, regulatory filings, and manufacturing oversight. In FY2025, the Company supported 3 marketed products – Crysvita, Dojolvi, and Mepsevii – while advancing its rare-disease pipeline. That mix makes execution speed, batch quality, and filing success central to revenue growth.
Outbound Logistics
Ultragenyx's outbound logistics depends on specialty distribution, direct delivery to treatment centers, and cold-chain shipping where needed. In 2025, with only a small set of commercial therapies serving rare-disease patients, each shipment had to match dose timing closely or therapy starts and refills could slip.
This makes fill accuracy, chain-of-custody, and on-time delivery a core value-chain step, not back-office work. For rare-disease drugs, even one late shipment can disrupt care for a patient who may have few treatment options.
Marketing and Sales
In 2025, Ultragenyx's marketing and sales stayed tightly focused on genetic centers, specialists, infusion sites, and payers, not broad consumer media. The company's selling work is built around education on diagnosis, genetic testing, and reimbursement, since rare-disease patients often need multiple steps before a prescription is written. This targeted model helps turn disease awareness into access and therapy starts.
Service
Ultragenyx's service layer covers reimbursement navigation, patient onboarding, adherence support, and safety follow-up after launch. In rare diseases, where patient pools are small and therapy costs are high, these services help cut abandonment and keep patients on treatment longer. That matters because even one lost patient can meaningfully move revenue in a niche franchise, so post-launch support is part of the commercial model, not just patient care.
Ultragenyx FY2025: Rare-Disease Growth Driven by Access and Execution
Ultragenyx's primary activities in FY2025 were focused on selling and supporting 3 marketed products: Crysvita, Dojolvi, and Mepsevii. It relied on specialist-targeted marketing, payer access work, and patient support to move rare-disease therapies through a small but complex market. With 9 approved medicines in its portfolio, execution speed and reimbursement success stayed central.
| FY2025 | Key data |
|---|---|
| Marketed products | 3 |
| Approved medicines | 9 |
| Core focus | Access, support, delivery |
What You See Is What You Get
Ultragenyx Reference Sources
This is the same Ultragenyx Value Chain Analysis document you'll receive after purchase – no surprises, just the full report. The preview below is taken directly from the actual file, so what you see is what you get. Unlock the complete, detailed version immediately after checkout.
Frequently Asked Questions
It shows a rare-disease model built around specialized R&D, targeted commercialization, and high-touch patient support. Ultragenyx currently relies on a small portfolio of marketed therapies and a broader pipeline across 3 modalities: enzyme replacement, gene therapy, and small molecules. That structure makes execution quality, reimbursement, and manufacturing continuity more important than scale.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.